Long-Term Outcomes with VMAT2 Inhibitors

Author(s):

Jason Noel, PharmD, MPA, BCPP,Julie Dopheide, PharmD, BCPP, FASHP

Panelists discuss how long-term open-label extension studies of VMAT2 inhibitors demonstrated sustained efficacy and tolerability of both deutetrabenazine (ARM-TD and AIM-TD extensions showing durable response over 3 years) and valbenazine (KINECT 4 showing maintained improvements through 48 weeks), with low discontinuation rates due to adverse events and no new safety signals emerging during extended treatment periods.

EP: 1.Optimizing Tardive Dyskinesia Care: Strategies to Advance Treatment Approaches

EP: 2.Diagnosing Tardive Dyskinesia

EP: 3.Impact of Tardive Dyskinesia on Quality of Life

EP: 4.Improving Outcomes Through Patient Education and Addressing Unmet Needs

EP: 5.Treatment Options for Tardive Dyskinesia

Now Viewing

EP: 6.Long-Term Outcomes with VMAT2 Inhibitors

EP: 7.Safety Profile of VMAT2 Inhibitors and Impact on Treatment Selection

EP: 8.Management of Tardive Dyskinesia and Comorbidities

EP: 9.Shared Decision-Making in Tardive Dyskinesia

EP: 10.Strategies for Optimizing Therapy

EP: 11.Patient Journey and the Role of the Pharmacist

EP: 12.Patient Counseling and Management of Adverse Events

EP: 13.Dosing and Titration Considerations

EP: 14.Enhancing Adherence and Collaborative Care

EP: 15.Educational Resources to Support Patients

Video series above is prompted by the following:

What did the following open-label extension studies reveal about the long-term safety and efficacy of the following VMAT2 inhibitors?
Deutetrabenazine
Valbenazine